Clinical Trial Update: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes investigating the combination of radiation therapy, an immunotherapy agent, and a PARP inhibitor for triple-negative breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Immunotherapy agent (PD-1/PD-L1 inhibitor)
• PARP inhibitor

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING